Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A2/PAF Acetylhydrolase

被引:36
作者
Liu, Jinbo [1 ]
Chen, Rui [1 ]
Marathe, Gopal K. [1 ]
Febbraio, Maria [1 ]
Zou, Weilin [1 ]
McIntyre, Thomas M. [1 ]
机构
[1] Cleveland Clin Lerner Coll Med, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA
关键词
PAF; oxidized phospholipids; phospholipid transport; lipoprotein-associated phospholipase A(2); PLASMA PAF-ACETYLHYDROLASE; LIPID MEDIATORS; FACTOR RECEPTOR; CELLS; DEFICIENCY; BLOOD; ROLES; INFLAMMATION; MACROPHAGES; METABOLISM;
D O I
10.1161/CIRCRESAHA.110.228742
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: The phospholipid platelet-activating factor (PAF) stimulates all cells of the innate immune system and numerous cardiovascular cells. A single enzyme (plasma PAF acetylhydrolase [PAF-AH] or lipoprotein-associated phospholipase [Lp-PL]A(2)) in plasma hydrolyzes PAF, but significant controversy exists whether its action is pro-or antiinflammatory and accordingly whether its inhibition will slow cardiovascular disease. Objective: We sought to define how PAF and related short-chain oxidized phospholipids turnover in vivo and the role of PAF acetylhydrolase/Lp-PLA(2) in this process. Methods and Results: [H-3-acetyl] PAF was hydrolyzed by murine or human plasma (t(1/2), 3 and 7 minutes, respectively), but injected [H-3-acetyl] PAF disappeared from murine circulation more quickly (t(1/2), < 30 seconds). [H-3]PAF clearance was unchanged in PAF receptor(-/-) animals, or over the first 2 half-lives in PAF-AH(-/-) animals. [H-3]PAF turnover was reduced by coinjecting excess unlabeled PAF or an oxidatively truncated phospholipid, and [H-3]PAF clearance was slowed in hyperlipidemic apolipoprotein (apo)E-/- mice with excess circulating oxidatively truncated phospholipids. [H-3]PAF, fluorescent NBD-PAF, or fluorescent oxidatively truncated phospholipid were primarily accumulated by liver and lung, and were transported into endothelium as intact phospholipids through a common mechanism involving TMEM30a . Conclusions: Circulating PAF and oxidized phospholipids are continually and rapidly cleared, and hence continually and rapidly produced. Saturable PAF receptor-independent transport, rather than just intravascular hydrolysis, controls circulating inflammatory and proapoptotic oxidized phospholipid mediators. Intravascular PAF has access to intracellular compartments. Inflammatory and proapoptotic phospholipids may accumulate in the circulation as transport is overwhelmed by substrates in hyperlipidemia. (Circ Res. 2011;108:469-477.)
引用
收藏
页码:469 / U155
页数:11
相关论文
共 49 条
[1]   INVIVO METABOLISM OF A NEW CLASS OF BIOLOGICALLY-ACTIVE PHOSPHOLIPIDS - 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE, A PLATELET ACTIVATING-HYPOTENSIVE PHOSPHOLIPID [J].
BLANK, ML ;
CRESS, EA ;
WHITTLE, T ;
SNYDER, F .
LIFE SCIENCES, 1981, 29 (08) :769-775
[2]   Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis [J].
Callea, L ;
Arese, M ;
Orlandini, A ;
Bargnani, C ;
Priori, A ;
Bussolino, F .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 94 (1-2) :212-221
[3]   PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry [J].
Casas, Juan P. ;
Ninio, Ewa ;
Panayiotou, Andrie ;
Palmen, Jutta ;
Cooper, Jackie A. ;
Ricketts, Sally L. ;
Sofat, Reecha ;
Nicolaides, Andrew N. ;
Corsetti, James P. ;
Fowkes, F. Gerry R. ;
Tzoulaki, Ioanna ;
Kumari, Meena ;
Brunner, Eric J. ;
Kivimaki, Mika ;
Marmot, Michael G. ;
Hoffmann, Michael M. ;
Winkler, Karl ;
Maerz, Winfred ;
Ye, Shu ;
Stirnadel, Heide A. ;
Khaw, Kay-Tee ;
Humphries, Steve E. ;
Sandhu, Manjinder S. ;
Hingorani, Aroon D. ;
Talmud, Philippa J. .
CIRCULATION, 2010, 121 (21) :2284-U74
[4]   Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis [J].
Chen, Jiawei ;
Yang, Lili ;
Foulks, Jason M. ;
Weyrich, Andrew S. ;
Marathe, Gopal K. ;
McIntyre, Thomas M. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (11) :2365-2376
[5]  
CHEN R, 2011, J IMMUNOL, P186
[6]   Cytotoxic phospholipid oxidation products - Cell death from mitochondrial damage and the intrinsic caspase cascade [J].
Chen, Rui ;
Yang, Lili ;
McIntyre, Thomas M. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (34) :24842-24850
[7]   BINDING OF PLATELET ACTIVATING FACTOR TO ALBUMIN [J].
CLAY, KL ;
JOHNSON, C ;
HENSON, P .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1046 (03) :309-314
[8]   Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker [J].
Corson, Marshall A. ;
Jones, Peter H. ;
Davidson, Michael H. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A) :41F-50F
[9]   A SIMPLE AND PRECISE METHOD FOR THE ROUTINE DETERMINATION OF PLATELET-ACTIVATING-FACTOR IN BLOOD AND URINE [J].
DEMOPOULOS, CA ;
ANDRIKOPOULOS, NK ;
ANTONOPOULOU, S .
LIPIDS, 1994, 29 (04) :305-309
[10]   HUMAN MACROPHAGES SECRETE PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE - A MECHANISM FOR RESOLUTION OF PULMONARY INFLAMMATION [J].
ELSTAD, MR ;
STAFFORINI, DM ;
PRESCOTT, SM ;
MCINTYRE, TM ;
ZIMMERMAN, GA .
CHEST, 1991, 99 (03) :S9-S10